PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
PROCEPT BioRobotics Corp. Announces Investor Event at 2024 AUA Annual Meeting in San Antonio, Texas
SAN JOSE, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today it will host an in-person investor event on Friday, May 3, 2024, at the Grand Hyatt Hotel in San Antonio, TX at the American Urological Association Annual Meeting from 8:00am to 9:30am Central Time.
加利福尼亚州圣何塞，2024 年 4 月 4 日（环球新闻专线）— PROCEPT BioRobotics Corporation（纳斯达克股票代码：PRCT）是一家专注于通过开发泌尿外科变革性解决方案来促进患者护理的手术机器人公司。该公司今天宣布，将于2024年5月3日星期五中部时间上午 8:00 至上午 9:30 在德克萨斯州圣安东尼奥的君悦酒店举行的美国泌尿外科协会年会上举办面对面的投资者活动。
Members of PROCEPT BioRobotics' management team presenting include:
PROCEPT BioRobotics 管理团队出席会议的成员包括：
- Reza Zadno – President & Chief Executive Officer
- Kevin Waters – Executive VP & Chief Financial Officer
- Sham Shiblaq – Executive VP & Chief Commercial Officer
- Barry Templin – Executive VP, Technology and Clinical Development
- Reza Zadno — 总裁兼首席执行官
- 凯文·沃特斯 — 执行副总裁兼首席财务官
- Sham Shiblaq — 执行副总裁兼首席商务官
- Barry Templin — 技术和临床开发执行副总裁
Clinical perspectives will also be provided by the following physicians:
以下医生还将提供临床观点：
- Dr. Inderbir Gill, Founding Executive Director for USC Urology and Chairman of Urological Cancer Surgery at Keck School of Medicine of USC
- Dr. Brian Helfand, Division of Urology, NorthShore University Health System
-
Dr. Lewis S. Kriteman, Partner and Executive VP, Georgia Urology
- Inderbir Gill 博士，创始执行董事 南加州大学泌尿外科 兼南加州大学凯克医学院泌尿外科主任
- 布莱恩·赫尔芬德博士，北岸大学卫生系统泌尿外科
- 乔治亚泌尿外科合伙人兼执行副总裁刘易斯·克里特曼博士
A live webcast of the event, as well as an archived recording, will be available on the "Investors" section of the Company's website at https://ir.procept-biorobotics.com/. The webcast will be archived and available for replay for at least 90 days after the event.
该活动的网络直播和存档录音将在公司网站的 “投资者” 栏目上公布，网址为 https://ir.procept-biorobotics.com/。网络直播将在活动结束后至少 90 天内存档并可供重播。
About PROCEPT BioRobotics Corporation
PROCEPT BioRobotics is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. PROCEPT BioRobotics develops, manufactures and sells the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. PROCEPT BioRobotics designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. The Company has developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 150 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy.
关于 PROCEPT BioRobotics 公司
PROCEPT BioRobotics是一家手术机器人公司，致力于通过开发泌尿科变革性解决方案来促进患者护理。PROCEPT BioRobotics开发、制造和销售AquaBeam机器人系统，这是一种先进的图像引导手术机器人系统，用于微创泌尿外科手术，最初的重点是治疗良性前列腺增生（BPH）。良性前列腺增生是最常见的前列腺疾病，在美国影响约4000万男性。PROCEPT BioRobotics 设计的水消融疗法旨在为因良性前列腺增生引起的下尿路症状或 LUTS 的男性提供有效、安全和持久的疗效，这些症状与前列腺大小和形状或外科医生的经验无关。该公司已经开发了大量且不断增长的临床证据，其中包括九项临床研究和150多份经过同行评审的出版物，这些证据支持了Aquablation疗法的益处和临床优势。
All surgical treatments have inherent and associated side effects. For a list of potential side effects visit https://aquablation.com/safety-information/.
所有手术治疗都有固有的和相关的副作用。有关潜在副作用的清单，请访问 https://aquablation.com/safety-information/。
Investor Contact:
Matt Bacso
VP, Investor Relations and Business Operations
m.bacso@procept-biorobotics.com
投资者联系人：
Matt Bacso
投资者关系和业务运营副总裁
m.bacso@procept-biorobotics.com